Amarin's Leadership: Who's at the Helm?

In this video, Motley Fool health-care analyst Max Macaluso takes a closer look at the leadership of Amarin (Nasdaq: AMRN  ) , maker of the triglyceride-lowering blockbuster drug Vascepa, and tells you what you need to know about leadership when considering whether to buy. Amarin's current CEO, Joseph Zakrzewski, has an ironic twist in his past that gives him key insight into Vascepa's biggest competitor. Since many consider Amarin to be a potential buyout target, Zakrzewski's unique knowledge will give him an edge if options like that come to the table.

The biotech space can make or break investors overnight, and when you're talking about Amarin,  the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2106416, ~/Articles/ArticleHandler.aspx, 4/19/2014 2:24:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement